1. Home
  2. FOLD vs LMAT Comparison

FOLD vs LMAT Comparison

Compare FOLD & LMAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FOLD
  • LMAT
  • Stock Information
  • Founded
  • FOLD 2002
  • LMAT 1983
  • Country
  • FOLD United States
  • LMAT United States
  • Employees
  • FOLD N/A
  • LMAT N/A
  • Industry
  • FOLD Biotechnology: Pharmaceutical Preparations
  • LMAT Medical/Dental Instruments
  • Sector
  • FOLD Health Care
  • LMAT Health Care
  • Exchange
  • FOLD Nasdaq
  • LMAT Nasdaq
  • Market Cap
  • FOLD 2.9B
  • LMAT 2.4B
  • IPO Year
  • FOLD 2007
  • LMAT 2006
  • Fundamental
  • Price
  • FOLD $9.80
  • LMAT $92.12
  • Analyst Decision
  • FOLD Strong Buy
  • LMAT Buy
  • Analyst Count
  • FOLD 8
  • LMAT 7
  • Target Price
  • FOLD $16.71
  • LMAT $92.83
  • AVG Volume (30 Days)
  • FOLD 2.8M
  • LMAT 216.4K
  • Earning Date
  • FOLD 11-06-2024
  • LMAT 10-31-2024
  • Dividend Yield
  • FOLD N/A
  • LMAT 0.69%
  • EPS Growth
  • FOLD N/A
  • LMAT 49.21
  • EPS
  • FOLD N/A
  • LMAT 1.82
  • Revenue
  • FOLD $493,671,000.00
  • LMAT $213,029,000.00
  • Revenue This Year
  • FOLD $34.30
  • LMAT $16.04
  • Revenue Next Year
  • FOLD $21.78
  • LMAT $9.62
  • P/E Ratio
  • FOLD N/A
  • LMAT $50.59
  • Revenue Growth
  • FOLD 32.58
  • LMAT 14.81
  • 52 Week Low
  • FOLD $9.02
  • LMAT $52.88
  • 52 Week High
  • FOLD $14.57
  • LMAT $109.58
  • Technical
  • Relative Strength Index (RSI)
  • FOLD 45.87
  • LMAT 36.20
  • Support Level
  • FOLD $9.41
  • LMAT $88.36
  • Resistance Level
  • FOLD $9.99
  • LMAT $102.66
  • Average True Range (ATR)
  • FOLD 0.35
  • LMAT 3.12
  • MACD
  • FOLD 0.03
  • LMAT -1.56
  • Stochastic Oscillator
  • FOLD 48.15
  • LMAT 20.50

About FOLD Amicus Therapeutics Inc.

Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.

About LMAT LeMaitre Vascular Inc.

LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes towards the proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems. LeMaitre generates the majority of its revenue in the United States.

Share on Social Networks: